Vertex Pharmaceuticals Accounts Payable increased by 6.0% to $489.30M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 10.0%, from $445.00M to $489.30M. Over 5 years (FY 2020 to FY 2025), Accounts Payable shows an upward trend with a 24.4% CAGR.
An increase can signal improved cash management or extended payment terms, while a decrease may indicate faster payments to suppliers or reduced purchasing activity.
This represents the short-term obligations owed to suppliers and vendors for goods and services received on credit. It i...
Standard current liability for all companies; comparable across industries based on days payable outstanding.
accounts_payable| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $127.53M | $127.86M | $195.00M | $173.60M | $198.00M | $126.90M | $303.90M | $323.20M | $363.00M | $375.90M | $364.90M | $351.40M | $327.90M | $395.80M | $413.00M | $445.00M | $442.30M | $420.30M | $461.70M | $489.30M |
| QoQ Change | — | +0.3% | +52.5% | -11.0% | +14.1% | -35.9% | +139.5% | +6.4% | +12.3% | +3.6% | -2.9% | -3.7% | -6.7% | +20.7% | +4.3% | +7.7% | -0.6% | -5.0% | +9.9% | +6.0% |
| YoY Change | — | — | — | — | +55.3% | -0.8% | +55.8% | +86.2% | +83.3% | +196.2% | +20.1% | +8.7% | -9.7% | +5.3% | +13.2% | +26.6% | +34.9% | +6.2% | +11.8% | +10.0% |